Search
nirsevimab-alip (Beyfortus)
Indications:
- treatment of respiratory syncytial virus (RSV
- neonates & infants born during or entering their 1st RSV season
- children <= 24 months of age vulnerable to severe RSV disease through their 2nd RSV season
Dosage:
- neonates & infants born during or entering their 1st RSV season
- 50 mg IM if < 5 kg
- 100 mg IM if >= 5 kg
- children <= 24 months of age vulnerable through their 2nd RSV season
- 2 doses 100 mg IM
Injection: 100 mg/mL in a single-dose pre-filled syringe
Mechanism of action:
- IgG1 monoclonal antibody, RSV F protein-directed fusion inhibitor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antiviral agent
pharmaceutical monoclonal antibody
References
- Highlights of Prescribing Information
Beyfortis (nirsevimab-alip) injection for intramuscular use
https://products.sanofi.us/beyfortus/beyfortus.pdf